Galway, Ireland-based AVeta — which has backing from Enterprise Ireland — develops the Vita AV platform for treating Genitourinary Syndrome of Menopause (GSM). (For more on how medtech is evolving in Ireland, read here.)
Vita AV, a first-of-its-kind, non-hormonal platform, addresses GSM, which the company says is a highly prevalent, underdiagnosed condition affecting the majority of post-menopausal women. It uses proven negative pressure therapy to provide rapid, sustained relief of symptoms.
The device utilizes a single-use intravaginal tip connected to an ergonomic handle. This interacts with an intuitive control module, calibrated to deliver precision negative pressure therapy and activate an immune response. The immune response restores vaginal tissue health by increasing blood supply, elasticity and moisture, relieving GSM symptoms.
The AVeta Medical solution is based on the proven science of negative pressure therapy, most often applied in wound-healing treatments. The treatment provides rapid and sustained relief of symptoms with no side effects.
The device employs a single use intravaginal tip connected to an ergonomic handle. This interacts with an intuitive control module which is calibrated to deliver precision negative pressure therapy which activates an immune response. The immune response restores vaginal tissue health by increasing blood supply, elasticity, and moisture, relieving the symptoms of GSM.
“AVeta Medical is poised to redefine the standard of care for millions of women living with GSM, and I’m excited to lead the company at this pivotal stage,” said Noblett. “With more than two decades in women’s health and medical device innovation, I see a rare opportunity to bring a first-of-its-kind, evidence-based therapy to market and build a scalable, high-growth organization around it.”
More about Dr. Karen Noblett as she takes over as CEO
“I am grateful for Eileen’s leadership as interim CEO, and the continued dedication of Paula Newell, founder & board director, and Brian Ledwith, director of R&D, whose contributions have laid a strong foundation for this next phase,” Noblett added.
Noblett brings more than 25 years of clinical, academic and medical technology experience to AVeta Medical. She’s a nationally recognized leader in urogynecology and pelvic floor disorders, according to the company.
Most recently, Noblett served as chief medical officer at Axonics. The company developed a sacral neuromodulation system for bladder and bowel disorders. Axonics sold to Boston Scientific for $3.7 billion last year. At Axonics, she oversaw clinical strategy, evidence generation, physician education and programs that supported technology adoption.
AVeta said her experience provides a strong foundation for scaling its clinical, regulatory and commercial strategy.
“Karen’s deep experience leading clinical programs, guiding regulatory strategy, and scaling med-tech innovation aligns directly with AVeta’s next phase of growth,” said Duffy.
